Change of Control: Why Getting it Right Matters Even More

Private biotechs' growing dependence on an M&A exit and the more lively acquisition activity throughout the sector means change of control provisions are being far more heavily negotiated than in the past, and it's critical to understand how far-reaching these provisions could be for biotechs hoping for successful exits.